Skip to main
HIMS
HIMS logo

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 29%
Buy 6%
Hold 47%
Sell 12%
Strong Sell 6%

Bulls say

Hims & Hers Health Inc demonstrated significant financial growth, achieving a total revenue increase of 95.1% year-over-year, with online revenue surging 98.3% to $470.8 million, exceeding expectations. The company also experienced substantial subscriber growth, adding 182,000 new subscribers in the quarter to reach 2.2 million, reflecting a 45% increase year-over-year. Furthermore, the shift towards personalized offerings has been notable, with 55.9% of subscribers now utilizing such services, contributing to a strong operational performance characterized by a robust combination of growth and profitability.

Bears say

Hims & Hers Health has expressed concerns regarding high prices in the healthcare market, which could hinder its ability to compete effectively against venture-backed companies that can undercut pricing to capture market share, potentially threatening customer retention and profitability. In addition, a reduction in gross margins due to pricing adjustments for GLP-1 drugs and rising costs could further pressure operating margins, which were reported at 8.9%, falling short of estimates. The company's elevated valuation, trading at over 4x EV/Sales, coupled with these financial challenges, raises significant concerns regarding its future performance.

HIMS has been analyzed by 17 analysts, with a consensus rating of Hold. 29% of analysts recommend a Strong Buy, 6% recommend Buy, 47% suggest Holding, 12% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 17 analysts, HIMS has a Hold consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.